18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
Giulia Polverari(University of Turin), Désirèe Deandreis, Andrea Veltri(Ospedale San Luigi Gonzaga), Virginia Liberini(University of Turin), Vincenzo Arena(Università Cattolica del Sacro Cuore), Manuela Racca(Fondazione Piemontese per la Ricerca sul Cancro Onlus), Maria Lucia Reale(Ospedale San Luigi Gonzaga), E. Gallio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Francesco Ceci(University of Turin), Valentina Bertaglia(Ospedale San Luigi Gonzaga), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Silvia Novello(University of Turin), Paola Scapoli(Fondazione Piemontese per la Ricerca sul Cancro Onlus), Osvaldo Rampado(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 97
Related Papers
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
|The Lancet Oncology|2014|948
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
|New England Journal of Medicine|2013|825